Recherche de Biomarqueurs prédictifs de réponse ou de résistance Dans Les Traitements Des Cancers du Sein
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 500
- 主要终点
- Number of Predictive Multimodal Biomarkers identified
研究概览
简要总结
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded treatment options, yet their efficacy varies depending on tumor subtype. This non-interventional study aims to identify novel predictive biomarkers of response or resistance to these emerging therapies. The Senocohort study will prospectively collect clinical, biological, imaging, and organoid-derived data from breast cancer patients, with a focus on hormone receptor-negative tumors. The ultimate goal is to improve precision medicine strategies and patient stratification
详细描述
Senocohort is a prospective, bicentric cohort study designed to collect clinico-biological data and establish a biobank of patient-derived tumor organoids (PDOs) from residual tissue samples obtained during routine care. The aim is to identify new multimodal biomarkers (molecular, cellular, and imaging) predictive of response or resistance to breast cancer therapies, with evaluation based on progression-free survival. The study targets an enriched population of hormone receptor-negative breast cancers, particularly triple-negative subtypes, which currently lack effective targeted treatments. Samples will be used for genomic analyses, PDO development, and circulating biomarker studies, with 10 years of clinical follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Histologically confirmed breast cancer
- •Managed at Saint-Louis Hospital
- •No opposition to participation in research
- •Affiliation to the French national health system
排除标准
- •Expressed opposition to research
- •Legal incapacity or under legal protection
- •Patients under State Medical Aid (AME)
研究组 & 干预措施
Breast Cancer Patients at Saint-Louis Hospital
Patients with newly diagnosed or recurrent breast cancer managed at the breast surgery and senology units. Residual tumor tissue, blood, and clinical data will be collected for analysis.
干预措施: Patients follow-up (Other)
结局指标
主要结局
Number of Predictive Multimodal Biomarkers identified
时间窗: Up to 10 years
Discovery and validation of molecular, cellular, and imaging biomarkers associated with response or resistance to therapies, evaluated on progression-free survival.
次要结局
- Overall Survival Analysis by Biomarker Subgroup(Up to 10 years)
- Multimodal biomarker performance(Up to 10 years)
- Drug Sensitivity in PDO Models(Up to 10 years)